Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on